Advertisement

Infection

, Volume 46, Issue 5, pp 721–724 | Cite as

A challenging case of carbapenemase-producing Klebsiella pneumoniae septic thrombophlebitis and right mural endocarditis successfully treated with ceftazidime/avibactam

  • Alessandra Iacovelli
  • Martina Spaziante
  • Samir Al Moghazi
  • Alessandra Giordano
  • Giancarlo Ceccarelli
  • Mario Venditti
Case Report

Abstract

Introduction

The emergence of carbapenemase-producing Klebsiella pneumonia (KPC-Kp) has become a significant problem in terms of public health and clinical outcome in many hospitals in Southern Europe. Treatment options are usually limited and effective treatment of infections caused by these pathogens is a considerable challenge for clinicians. Ceftazidime–avibactam has been recently approved for the treatment of difficult-to-treat infections due to aerobic Gram-negative organisms in patients with limited treatment options.

Case report

We reported the first case of KPC-Kp septic thrombophlebitis and right atrial endocarditis associated with metastatic lung abscesses successfully treated with a prolonged ceftazidime/avibactam plus ertapenem treatment course, suggesting that this combination therapy could be safe and effective for serious Gram-negative infections. Interestingly, we also observed an apparent discrepancy between clinical and microbiological courses: the patient became rapidly afebrile; hemodynamically stable and his procalcitonin levels showed a prompt decreasing trend. Nevertheless, blood cultures remained persistently positive for a prolonged period.

Conclusion

In conclusion, ceftazidime–avibactam plus ertapenem was a safe and effective therapy of serious endovascular infection due to KPC-Kp. Moreover, in this setting, follow-up blood cultures might represent an irreplaceable tool to guide the therapy.

Keywords

Klebsiella pneumoniae Thrombophlebitis Endocarditis Ceftazidime–avibactam Procalcitonin 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that there is no conflict of interest.

References

  1. 1.
    Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH, International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169:463–73.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Leone S, Ravasio V, Durante-Mangoni E, Crapis M, Carosi G, Scotton PG, Barzaghi N, Falcone M, Chinello P, Pasticci MB, Grossi P, Utili R, Viale P, Rizzi M, Suter F. Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian study on endocarditis. Infection 2012;40:527–35.CrossRefPubMedGoogle Scholar
  3. 3.
    Falcone M, Tiseo G, Durante-Mangoni E, Ravasio V, Barbaro F, Ursi MP, Pasticci MB, Bassetti M, Grossi P, Venditti M, Rizzi M. Risk factors and outcomes of endocarditis due to non-HACEK Gram-negative bacilli: data from the prospective multicenter italian endocarditis study cohort. Antimicrob Agents Chemother. 2018.  https://doi.org/10.1128/AAC.02208-17.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Morpeth S, Murdoch D, Cabell CH, Karchmer AW, Pappas P, Levine D, Nacinovich F, Tattevin P, Fernández-Hidalgo N, Dickerman S, Bouza E, del Río A, Lejko-Zupanc T, de Oliveira Ramos A, Iarussi D, Klein J, Chirouze C, Bedimo R, Corey GR, Fowler VG Jr, International Collaboration on Endocarditis Prospective Cohort Study (ICE-PCS) Investigators. Non-HACEK Gram-negative bacillus endocarditis. Ann Intern Med. 2007;147:829–35.CrossRefPubMedGoogle Scholar
  5. 5.
    Camargo JF, Simkins J, Beduschi T, Tekin A, Aragon L, Pérez-Cardona A, et al. Successful treatment of carbapenemase-producing pandrug-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2015;59:5903–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, Cantón R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Monnet DL, European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. Lancet Infect Dis. 2017;17:153–63.CrossRefPubMedGoogle Scholar
  7. 7.
    Giske CG, Monnet DL, Cars O, Carmeli Y. Clinical and economic impact of common multidrug-resistant Gram-negative bacilli. Antimicrob Agents Chemother. 2008;52:813–21.CrossRefPubMedGoogle Scholar
  8. 8.
    Nordmann P, Naas T, Poirel L. Global spread of carbapenemase producing Enterobacteriaceae. Emerg Infect Dis. 2011;17:1791–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228–36.CrossRefPubMedGoogle Scholar
  10. 10.
    Giacobbe DR, Del Bono V, Mikulska M, Gustinetti G, Marchese A, Mina F, Signori A, Orsi A, Rudello F, Alicino C, Bonalumi B, Morando A, Icardi G, Beltramini S, Viscoli C, San Martino Antimicrobial Stewardship Group. Impact of a mixed educational and semi-restrictive antimicrobial stewardship project in a large teaching hospital in Northern Italy. Infection. 2017;45:849–56.CrossRefPubMedGoogle Scholar
  11. 11.
    Murri R, Fiori B, Spanu T, Mastrorosa I, Giovannenze F, Taccari F, Palazzolo C, Scoppettuolo G, Ventura G, Sanguinetti M, Cauda R, Fantoni M. Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series. Infection. 2017;45:209–13.CrossRefPubMedGoogle Scholar
  12. 12.
    Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S, et al. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect. 2010;16:102–11.CrossRefPubMedGoogle Scholar
  13. 13.
    Falcone M, Paterson D. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016;71:2713–22.CrossRefPubMedGoogle Scholar
  14. 14.
    Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Doi Y, Kreiswirth BN, Clancy CJ. Ceftazidime–avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumonia bacteremia. Antimicrob Agents Chemother. 2017;61:e00883–17.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Tumbarello M, Trecarichi EM, Corona A, De Rosa FG, Bassetti M, Mussini C, Menichetti F, Viscoli C, Campoli C, Venditti M, De Gasperi A, Mularoni A, Tascini C, Parruti G, Pallotto C, Sica S, Concia E, Cultrera R, De Pascale G, Capone A, Antinori S, Corcione S, Righi E, Losito AR, Digaetano M, Amadori F, Giacobbe DR, Ceccarelli G, Mazza E, Raffaelli F, Spanu T, Cauda R, Viale P. Efficacy of ceftazidime–avibactam salvage therapy in patients with infections caused by KPC-producing Klebsiella pneumoniae. Clin Infect Dis. 2018.  https://doi.org/10.1093/cid/ciy492.CrossRefPubMedGoogle Scholar
  16. 16.
    European Committee on Antimicrobial Susceptibility Testing (EUCAST). EUCAST warnings concerning antimicrobial susceptibility testing products or procedures. Växjö: European Committee on Antimicrobial Susceptibility Testing; 2018. http://www.eucast.org/ast_of_bacteria/warnings. Accessed 15 June 2018.
  17. 17.
    Matuschek E, Åhman J, Webster C, Kahlmeter G. Antimicrobial susceptibility testing of colistin—evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. Clin Microbiol Infect. 2017.  https://doi.org/10.1016/j.cmi.2017.11.020.CrossRefPubMedGoogle Scholar
  18. 18.
    Gaibani P, Lewis RE, Volpe SL, Giannella M, Campoli C, Landini MP, Viale P, Re MC, Ambretti S. In vitro interaction of ceftazidime–avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis. 2017;65:1–3.CrossRefPubMedGoogle Scholar
  19. 19.
    Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. Emergence of ceftazidime–avibactam resistance and restoration of carbapenem susceptibility in Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: a case report and review of literature. Open Forum Infect Dis. 2017;4:ofx101.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Ceccarelli G, Giuliano S, Falcone M, Venditti M. Follow-up blood cultures: a 2.0 diagnostic tool in patients with Gram-negative bacteremia and septic thrombophlebitis. Clin Infect Dis. 2018;66:1154–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Yan ST, Sun LC, Jia HB, Gao W, Yang JP, Zhang GQ. Procalcitonin levels in bloodstream infections caused by different sources and species of bacteria. Am J Emerg Med. 2017;35:579–83.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018
corrected publication July 2018

Authors and Affiliations

  • Alessandra Iacovelli
    • 1
  • Martina Spaziante
    • 2
  • Samir Al Moghazi
    • 1
  • Alessandra Giordano
    • 1
  • Giancarlo Ceccarelli
    • 1
  • Mario Venditti
    • 1
  1. 1.Department of Public Health and Infectious Diseases“Sapienza” University of RomeRomeItaly
  2. 2.Department of Clinical Medicine“Sapienza” University of RomeRomeItaly

Personalised recommendations